Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 29, 2026, 1:09 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 46 matching trials from the live ClinicalTrials.gov search.
Conditions
Myocardial Ischemia, Coronary Artery Disease, Arteriosclerosis, Chronic Stable Angina
Interventions
Ranolazine, Placebo
Drug
Lead sponsor
East Carolina University
Other
Eligibility
21 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Greenville, North Carolina
Conditions
Peripheral Vascular Diseases, Chronic Total Occlusion of Artery of the Extremities
Interventions
Drug-eluting stent, Bare metal stent
Device
Lead sponsor
North Texas Veterans Healthcare System
Federal
Eligibility
18 Years to 90 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
2
States / cities
Dallas, Texas
Conditions
Chronic Total Occlusion, Occlusion
Interventions
Chronic total occlusion percutaneous coronary intervention
Procedure
Lead sponsor
Minneapolis Heart Institute Foundation
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Minneapolis, Minnesota
Terminated No phase listed Observational Accepts healthy volunteers

REduction of Contrast Via DyeVert Used in CTO Procedures

NCT03118544
Conditions
Chronic Total Occlusion of Coronary Artery
Interventions
DyeVert System
Device
Lead sponsor
Minneapolis Heart Institute Foundation
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
3
States / cities
Minneapolis, Minnesota
Conditions
Chronic Total Occlusion of Artery of the Extremities
Interventions
1. CROSSER System
Device
Lead sponsor
C. R. Bard
Industry
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
8
States / cities
Washington D.C., District of Columbia • Des Moines, Iowa • Detroit, Michigan + 5 more
Conditions
Heart Failure, Chronic Heart Failure
Interventions
Argus Oximetry System
Device
Lead sponsor
NIRSense Inc.
Industry
Eligibility
18 Years to 85 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Jackson, Mississippi
Conditions
Symptomatic Femoro-popliteal Chronic Total Occlusion
Interventions
TruePath CTO Device, CROSSER CTO Device
Device
Lead sponsor
Yale University
Other
Eligibility
18 Years to 100 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
New Haven, Connecticut
Conditions
Atherosclerosis, Peripheral Artery Disease, Intermittent Claudication, Chronic Total Aterial Occlusion
Interventions
MS-325 Injection (Gadofosveset Trisodium)
Drug
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2007
U.S. locations
1
States / cities
Bethesda, Maryland
Completed Not applicable Interventional Results available

The Asahi Intecc PTCA Chronic Total Occlusion Study

NCT02379923
Conditions
Coronary Artery Disease, Coronary Artery Chronic Total Occlusion
Interventions
Crossing of Coronary Artery CTO
Device
Lead sponsor
Asahi Intecc USA Inc
Industry
Eligibility
18 Years and older
Enrollment
163 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
12
States / cities
Phoenix, Arizona • Loveland, Colorado • Atlanta, Georgia + 8 more
Conditions
Coronary Occlusion
Interventions
NovaCross
Device
Lead sponsor
Nitiloop Ltd.
Industry
Eligibility
25 Years to 80 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
3
States / cities
Little Rock, Arkansas • New York, New York • York, Pennsylvania
Conditions
Chronic Total Occlusion of Coronary Artery, Chronic Angina
Interventions
VasoStar guidewire system
Device
Lead sponsor
VasoStar, LLC
Industry
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
2
States / cities
Atlanta, Georgia • Akron, Ohio
Conditions
Chronic Total Occlusion
Interventions
CTO Crossing and Percutaneous transluminal angioplasty
Device
Lead sponsor
BridgePoint Medical
Industry
Eligibility
18 Years and older
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
10
States / cities
Phoenix, Arizona • Los Angeles, California • Torrance, California + 7 more
Conditions
Chronic Total Occlusion of Artery of the Extremities
Interventions
FastWire System - Peripheral
Device
Lead sponsor
Versono Medical Ltd
Industry
Eligibility
18 Years to 85 Years
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
6
States / cities
Wilmington, Delaware • Cocoa, Florida • Davenport, Iowa + 3 more
Completed Phase 4 Interventional Results available

XIENCE V® USA Dual Antiplatelet Therapy (DAPT) Cohort

NCT01106534
Conditions
Chronic Total Occlusion of Coronary Artery, Vascular Disease, Myocardial Ischemia, Coronary Artery Stenosis, Coronary Disease, Coronary Artery Disease, Coronary Restenosis
Interventions
placebo + aspirin, clopidogrel + aspirin OR prasugrel + aspirin, XIENCE V Everolimus Eluting Coronary Stent System (XIENCE V EECSS)
Drug · Device
Lead sponsor
Abbott Medical Devices
Industry
Eligibility
18 Years and older
Enrollment
870 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
144
States / cities
Birmingham, Alabama • Fairhope, Alabama • Scottsdale, Arizona + 126 more
Conditions
Chronic Total Occlusion, Atherosclerosis, Coronary Artery Disease, Peripheral Artery Disease
Interventions
Roxwood Anchoring Catheters, Acetylsalicylic Acid, Heparin
Device · Drug
Lead sponsor
Boston Scientific Corporation
Industry
Eligibility
25 Years to 80 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
11
States / cities
Phoenix, Arizona • Gainesville, Florida • Hobart, Indiana + 8 more
Completed Not applicable Interventional

STAR and Deferred Stenting Study

NCT05089864
Conditions
Coronary Occlusion, Coronary Stenosis, Coronary Restenosis
Interventions
Stent Placement Timing - Early, Stent Placement Timing - Late
Other
Lead sponsor
Saint Luke's Health System
Other
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
Kansas City, Missouri
Conditions
Peripheral Arterial Disease
Interventions
RA-308 Excimer Laser and DABRA Catheter
Device
Lead sponsor
Ra Medical Systems
Industry
Eligibility
18 Years and older
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
3
States / cities
El Centro, California • San Diego, California • Hattiesburg, Mississippi
Conditions
Ischemic Heart Disease
Interventions
Not listed
Lead sponsor
Piedmont Healthcare
Other
Eligibility
18 Years and older
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
Atlanta, Georgia
Conditions
Chronic Total Occlusion of Coronary Artery
Interventions
NovaCross
Device
Lead sponsor
Nitiloop Ltd.
Industry
Eligibility
18 Years to 80 Years
Enrollment
145 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
4
States / cities
Little Rock, Arkansas • Naperville, Illinois • New York, New York + 1 more
Conditions
Chronic Pain, Opioid Use, Adductor Canal Block, Total Knee Arthroplasty
Interventions
ambIT pump with catheter, ambIT pump with sham catheter
Device
Lead sponsor
Hospital for Special Surgery, New York
Other
Eligibility
18 Years to 75 Years
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
New York, New York
Active, not recruiting Not applicable Interventional

Invest-CTO PCI Trial

NCT04774913
Conditions
Chronic Total Occlusion of Coronary Artery, Angina Pectoris, Quality of Life, PROM
Interventions
Chronic total occlusion(CTO) percutaneous coronary intervention (PCI)
Procedure
Lead sponsor
Haukeland University Hospital
Other
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
New York, New York
Terminated No phase listed Observational Accepts healthy volunteers

Change in Exercise Capacity as Measured by Peak Oxygen Uptake After CTO PCI

NCT02499666
Conditions
Coronary Artery Disease, Angina Pectoris
Interventions
Percutaneous Coronary Intervention, Coronary stent, Clopidogrel
Procedure · Device · Drug
Lead sponsor
Henry Ford Health System
Other
Eligibility
18 Years to 90 Years
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2017
U.S. locations
1
States / cities
Detroit, Michigan
Completed No phase listed Observational Accepts healthy volunteers

Evaluation Inhaled Corticosteroids on Exhaled Nitric Oxide Gas Exchange

NCT00568347
Conditions
COPD
Interventions
fluticasone 100mcg/ salmeterol 50mcg, fluticasone 250/salmeterol 50, Salmeterol, salmeterol and fluticasone propionate
Drug
Lead sponsor
Arthur F Gelb MD
Individual
Eligibility
20 Years to 85 Years
Enrollment
39 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2013
U.S. locations
1
States / cities
Lakewood, California
Conditions
Chronic Total Occlusion
Interventions
Directly measure microvascular function using direct coronary flow measurements
Other
Lead sponsor
University of Chicago
Other
Eligibility
21 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Chicago, Illinois